JS105
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for JS105, covering 2025-07-25 to 2025-12-30. Get the full timeline:
Most recent: Clinical Trial Update: A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer. [Phase 3]